ClinicalTrials.gg
RecruitingNCT07288138Updated Nov 9, 2026

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 2 interventional study of Placebo and ECC4703 in Metabolic Dysfunction-associated Steatohepatitis, sponsored by Eccogene. Recruiting at 70 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Eccogene · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 9, 2026Site recruiting status changed6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Planned enrollment
46th of 269
160 · median 48
Started
2025
with 9 others
Phase 2
62 of 368
8 open now
Primary completion
2027-09
later than 22 of 57 live
Registered
359th of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 46th largest by planned enrollment of the 269 interventional ones that give a count, is one of 10 that started in 2025, is one of 62 in phase 2, reaches primary completion later than 22 of the 57 other live ones, and was the 359th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 152 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis

Keywords

  • Liver Disease
  • Nonalcoholic Steatohepatitis
  • ECC0509
  • ECC4703
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults between 18 and 75 years of age, inclusive, who can provide written and comply with study procedures.
  2. Diagnosis of presumed MASH based on: liver within 180 days prior to screening showing an NAFLD activity score (NAS) of ≥3 and a fibrosis score (F) of F1-3 OR FibroScan® CAP >280 dB/m at screening with presence of metabolic risk factors.
  3. Evidence of hepatic steatosis confirmed by FibroScan® LSM > 7 kPa and \< 20 kPa and MRI-PDFF >8% at screening.
  4. >25 kg/m\^2 to \<50 kg/m\^2 (non-Asian); BMI ≥23.0 to \<50.0 kg/m\^2 (Asian).
  5. ≥60 U/L at the first screening visit and stability of ALT and AST levels during the screening period.
  6. Estimated (eGFR) ≥60 mL/min/1.73m\^2 (Chronic Kidney Disease Epidemiology Collaboration, [CKD-EPI]).
  7. Stable body weight (no >5% change) for at least 6 months prior to screening.
  8. Willing to comply with requirements (as applicable to males and females of ).
  9. In the opinion of the investigator, able to participate safely and complete required MRI/biomarker assessments.

Exclusion criteria

Exclusion Criteria:

  1. Chronic liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH, including alcoholic liver disease, hepatitis, cholestatic disease, genetic liver diseases, or drug-induced liver injury.
  2. Presence of cirrhosis on liver histology according to the assessment of the central reader, and/or cross-sectional imaging evidence consistent with cirrhosis and/or portal hypertension (e.g, nodular liver contour; portosystemic collaterals, ascites, splenomegaly; known presence or history of esophageal varices; and/or elastography evidence consistent with cirrhosis).
  3. and/or AST >5× (ULN) or ALP >2×ULN at screening.
  4. thyroid or adrenal dysfunction, including uncontrolled hypothyroidism, hyperthyroidism, or adrenal disorders.
  5. Type 1 diabetes, >9.5%, or unstable type 2 diabetes requiring medication changes within 90 days.
  6. Use of medications that affect liver fat or fibrosis (e.g., Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) not on a stable dose, pioglitazone, obeticholic acid, high-dose vitamin E, hepatotoxic drugs) within protocol-specified .
  7. Significant alcohol use within 1 year prior to screening.
  8. Recent cardiovascular events, including myocardial infraction (MI), stroke, unstable angina, heart failure ( [NYHA III-IV]), or uncontrolled arrhythmia.
  9. Current or recent serious psychiatric illness, including psychosis, active suicidal ideation, or suicide attempt within 5 years.
  10. Pregnancy, breastfeeding, or conditions that increase risk or interfere with study procedures, including MRI or other investigator-determined safety concerns.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    ECC4703 Low Dose

    Drug: ECC4703

  • Experimental
    ECC4703 High Dose

    Drug: ECC4703

  • Experimental
    ECC4703 High Dose + ECC0509 High Dose

    Drug: ECC0509 · Drug: ECC4703

  • Experimental
    ECC0509 Low Dose

    Drug: ECC0509

  • Experimental
    ECC0509 High Dose

    Drug: ECC0509

Interventions

  • DrugPlacebo

    Placebo will be administered as matching oral capsules.

  • ECC4703 will be administered as oral capsules.

  • ECC0509 will be administered as oral capsules.

  • ECC4703 will be administered as oral capsules.

06

What researchers measure

Primary outcomes

  1. Relative Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC4703 Monotherapy Versus Placebo

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Absolute Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC4703 Monotherapy Versus Placebo

    Time frame: Baseline and Week 12

  2. Relative Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  3. Absolute Change From Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  4. Percentage of Participants With ≥30%, ≥50%, and ≥70% Relative Reduction and Normalization (<5%) in Liver Fat Content by MRI-PDFF, Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  5. Change From Baseline in Alanine Aminotransferase (ALT), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  6. Percentage of Participants Achieving ≥17-unit Reduction in ALT, Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Week 12

  7. Percentage of Participants With 30% Reduction in MRI-PDFF, Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Week 12

  8. Change from Baseline in Aspartate Aminotransferase (AST), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  9. Change from Baseline in Alkaline Phosphatase (ALP), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  10. Change from Baseline in Gamma-glutamyl Transferase (GGT), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  11. Change from Baseline in Fibrosis-4 Index (FIB-4), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  12. Change from Baseline in AST to Platelet Ratio Index (APRI), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  13. Change from Baseline in FibroScan AST Score (FAST), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  14. Change from Baseline in Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  15. Change from Baseline in Enhanced Liver Fibrosis (ELF) Score, Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  16. Change from Baseline in MASH Resolution Index, Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  17. Change from Baseline in FibroScan Liver Stiffness Measurement (LSM), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  18. Change from Baseline in FibroScan Controlled Attenuation Parameter (CAP), Comparing ECC4703 and ECC0509 Monotherapy Versus Placebo, and the Combination of ECC4703 and ECC0509 Versus Each Component

    Time frame: Baseline and Week 12

  19. Change from Baseline in Total Cholesterol (TC), Triglycerides (TG), High-density Lipoprotein (HDL), Low-density Lipoprotein (LDL) and Apoprotein B (ApoB)

    Time frame: Baseline to Week 12

  20. Change from Baseline in Lipoprotein(a) (Lp[a]) Profiles

    Time frame: Baseline to Week 12

  21. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 12

  22. Change from Baseline in Fasting Plasma Glucose (FPG)

    Time frame: Baseline to Week 12

  23. Change from Baseline in Fasting Insulin

    Time frame: Baseline to Week 12

  24. Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Profiles

    Time frame: Baseline to Week 12

  25. Change from Baseline in Body Weight

    Time frame: Baseline to Week 12

  26. Change from Baseline Body Mass Index (BMI)

    Time frame: Baseline to Week 12

  27. Change from Baseline in Plasma Methylamine

    Time frame: Baseline to Week 12

  28. Change from Baseline in Cytokeratin-18 (CK-18)

    Time frame: Baseline to Week 12

  29. Change from Baseline in C-telopeptide of Type III Collagen (CTX-III)

    Time frame: Baseline to Week 12

  30. Change from Baseline in N-terminal Pro-peptide of Type III Collagen (Pro-C3)

    Time frame: Baseline to Week 12

  31. Change in Ratio of Pro-C3

    Time frame: Week 12

  32. Change in Ratio of CTX-III

    Time frame: Week 12

  33. Change from Baseline in Chronic Liver Disease Questionnaire (CLDQ)

    Time frame: Baseline and Week 12

  34. Change from Baseline in Short-form Liver Disease Quality of Life (SF-LDQOL)

    Time frame: Baseline to Week 12

  35. Plasma Concentration of ECC4703 and ECC0509

    Time frame: Day 1, Weeks 2, 4, 6, 8, and 12

07

Study locations

67 of 70 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 41 phase 2 interventional studies under Liver Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 29, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added. 2 sites changed recruiting status (2 now active, not recruiting)
Show 2 sites
  • Digestive Research Alliance of Michiana · South Bend, United StatesRecruiting→Active, not recruiting
  • GI Alliance Richmond · Richmond, United StatesRecruiting→Active, not recruiting
Show 6 added (6 United States)
  • GI Alliance Glenview · Glenview, United States
  • GI Alliance Gurnee · Gurnee, United States
  • GI Alliance Digestive Health Associates of Texas - Garland · Garland, United States
  • GI Alliance Webster · Webster, United States
  • Dayton Gastroenterology - Englewood · Dayton, United States
  • Gastro One · Cordova, United States
across 2 updates, Oct 9, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    2 sites added. 2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • Digestive Research Alliance of Michiana · South Bend, United StatesRecruiting→Active, not recruiting
    • GI Alliance Richmond · Richmond, United StatesRecruiting→Active, not recruiting
    Show 2 added (2 United States)
    • Dayton Gastroenterology - Englewood · Dayton, United States
    • Gastro One · Cordova, United States
    + 1 other change: verification date
  2. Oct 9, 2026
    4 sites added
    Show 4 added (4 United States)
    • GI Alliance Glenview · Glenview, United States
    • GI Alliance Gurnee · Gurnee, United States
    • GI Alliance Digestive Health Associates of Texas - Garland · Garland, United States
    • GI Alliance Webster · Webster, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288138
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 15, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 29, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Eccogene Clinical Trials
Contact
contact@eccogene.com
86-21-61053022
Eccogene Clinical Trials
study director · Eccogene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ECC4703 · ECC0509

Start the discussion